贝伐珠单抗联合XELOX方案对结直肠癌根治术后患者血管内皮生长因子水平的影响

Effect of Bevacizumab Combined with XELOX Scheme on the Level of Vascular Endothelial Growth Factor in Patients with Olorectal Cancer after Radical Resection

目的:观察贝伐珠单抗联合XELOX方案对结直肠癌根治术后患者血管内皮生长因子(VEGF)水平的影响。方法:选取新余市中医院内三科2019年4月—2022年2月收治的行结直肠癌根治术治疗的89例结直肠癌患者,用随机数字表法将其分为对照组(n=45)、治疗组(n=44)。对照组用XELOX方案治疗,治疗组用贝伐珠单抗联合XELOX方案治疗。对比两组肿瘤标志物水平、VEGF水平、毒副反应及复发率。结果:治疗组治疗3个周期后的癌胚抗原(CEA)、糖类抗原(CA)19-9、CA242水平均较对照组低,差异均有统计学意义(P<0.05);治疗组治疗3个周期后的VEGF水平较对照组低,差异有统计学意义(P<0.05);两组胃肠道症状、骨髓抑制、脱发、肝功能异常、白细胞降低发生率和毒副反应总发生率及复发率比较,差异均无统计学意义(P>0.05)。结论:结直肠癌根治术后患者采用贝伐珠单抗联合XELOX方案治疗利于下调肿瘤标志物水平,降低VEGF水平,且药物安全性好。

Objective:To observe the effect of Bevacizumab combined with XELOX scheme on the level of vascular endothelial growth factor(VEGF)in patients with colorectal cancer after radical resection.Method:A total of 89 patients with colorectal cancer who underwent radical resection of colorectal cancer in the Internal Medicine Three Department of Xinyu Hospital of Traditional Chinese Medicine from April 2019 to February 2022 were selected and divided into control group(n=45)and treatment group(n=44)according to random number table method.The control group was treated with XELOX scheme,the treatment group was treated with Bevacizumab combined with XELOX scheme.The levels of tumor markers,VEGF,toxic and side reaction and relapse rate were compared between the two groups.Result:After 3 cycles of treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen(CA)19-9 and CA242 in the treatment group were lower than those in the control group,the differences were statistically significant(P<0.05).After 3 cycles of treatment,the VEGF level in the treatment group was lower than that in the control group,the difference was statistically significant(P<0.05).There were no significant differences in the incidence of gastrointestinal symptoms,myelosuppression,alopecia,abnormal liver function,leukocyte decreased and total incidence of toxic and relapse rate between the two groups(P>0.05).Conclusion:Bevacizumab combined with XELOX scheme in patients with colorectal cancer after radical surgery is beneficial to down-regulate the levels of tumor markers and reduce the level of VEGF,and the drug safety is good.